{"nctId":"NCT02620020","briefTitle":"A Study to Determine the Efficacy and Safety of Fasinumab for the Treatment of Adults With Chronic Low Back Pain","startDateStruct":{"date":"2016-01-26","type":"ACTUAL"},"conditions":["Low Back Pain"],"count":563,"armGroups":[{"label":"Fasinumab 6 mg SC Q4W and Placebo IV Q8W","type":"EXPERIMENTAL","interventionNames":["Drug: Fasinumab","Drug: placebo"]},{"label":"Fasinumab 9 mg SC Q4W and Placebo IV Q8W","type":"EXPERIMENTAL","interventionNames":["Drug: Fasinumab","Drug: placebo"]},{"label":"Fasinumab 9 mg IV Q8W and Placebo SC Q4W","type":"EXPERIMENTAL","interventionNames":["Drug: Fasinumab","Drug: placebo"]},{"label":"Placebo SC Q4W and Placebo IV Q8W","type":"EXPERIMENTAL","interventionNames":["Drug: placebo"]}],"interventions":[{"name":"Fasinumab","otherNames":["REGN475"]},{"name":"placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n1. Male or female ≥35 years of age at the screening visit\n2. Clinical diagnosis of chronic moderate to severe LBP (nonradiculopathic)for ≥3 months\n3. History of regular analgesic medication\n4. History of inadequate pain relief or intolerance to analgesics used for chronic LBP\n5. Willing to discontinue current pain medication\n\nKey Exclusion Criteria:\n\n1. History of lumbosacral radiculopathy within the past 2 years\n2. Evidence on baseline lumbar spine magnetic resonance imaging of potentially confounding conditions\n3. Recent use of longer acting pain medications\n4. Evidence of destructive arthropathy\n5. Other medical conditions that may interfere with participation or accurate assessments during the trial","healthyVolunteers":false,"sex":"ALL","minimumAge":"35 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline to Week 16 in the Average Daily Low Back Pain Index Numeric Rating Scale (LBPI NRS) Score","description":"Average daily low back pain (LBP) was assessed on an 11-point numeric rating scale (NRS) and was defined as the average of the non-missing daily LBPI NRS scores for the 7 days before and including nominal visit. Participants described their average low back pain during the past 24 hours on a scale ranging from 0 (no pain) to 10 (worst possible pain), where higher scores indicate higher pain.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.7","spread":"0.23"},{"groupId":"OG001","value":"-2.0","spread":"0.23"},{"groupId":"OG002","value":"-2.5","spread":"0.22"},{"groupId":"OG003","value":"-2.4","spread":"0.22"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Weeks 2, 4, 8, and 12 in the Average Low Back Pain Index Numeric Rating Scale Score (LBPI NRS)","description":"Average daily low back pain (LBP) was assessed on an 11-point numeric rating scale (NRS) and was defined as the average of the non-missing daily LBPI NRS scores for the 7 days before and including nominal visit. Participants described their average low back pain during the past 24 hours on a scale ranging from 0 (no pain) to 10 (worst possible pain), where higher scores indicate higher pain.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.9","spread":"0.17"},{"groupId":"OG001","value":"-1.3","spread":"0.17"},{"groupId":"OG002","value":"-1.6","spread":"0.17"},{"groupId":"OG003","value":"-1.6","spread":"0.16"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.9","spread":"0.17"},{"groupId":"OG001","value":"-1.5","spread":"0.17"},{"groupId":"OG002","value":"-2.0","spread":"0.17"},{"groupId":"OG003","value":"-1.9","spread":"0.16"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.2","spread":"0.19"},{"groupId":"OG001","value":"-1.8","spread":"0.19"},{"groupId":"OG002","value":"-2.3","spread":"0.19"},{"groupId":"OG003","value":"-2.2","spread":"0.19"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.5","spread":"0.21"},{"groupId":"OG001","value":"-2.0","spread":"0.21"},{"groupId":"OG002","value":"-2.6","spread":"0.21"},{"groupId":"OG003","value":"-2.5","spread":"0.21"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 16 in Roland Morris Disability Questionnaire (RMDQ) Total Score","description":"The RMDQ is a self-administered, widely used health status measure for lower back pain (LBP). It measures pain and function, using 24 items describing limitations to everyday life that can be caused by LBP. The score of the RMDQ is the total number of items checked - that is from a minimum of 0 (no disability) to a maximum of 24 (maximum disability), where lower scores indicative of better function.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.8","spread":"0.54"},{"groupId":"OG001","value":"-6.0","spread":"0.54"},{"groupId":"OG002","value":"-5.8","spread":"0.51"},{"groupId":"OG003","value":"-6.3","spread":"0.51"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 16 in the Patient Global Assessment (PGA) of Low Back Pain (LBP) Score","description":"The PGA of LBP is a participant assessed 5 point Likert scale of LBP ranging from 0-5 where 1=very well; 2=well; 3=fair; 4=poor; and 5=very poor.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.7","spread":"0.10"},{"groupId":"OG001","value":"-0.9","spread":"0.10"},{"groupId":"OG002","value":"-0.8","spread":"0.10"},{"groupId":"OG003","value":"-1.0","spread":"0.09"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":140},"commonTop":["Arthralgia","Headache","Nasopharyngitis","Paraesthesia","Pain in extremity"]}}}